Ilya Pokataev, Alexey Tryakin, Alexandra Tjulandina, Mikhail Fedyanin, Sergei Tjulandin
{"title":"奥沙利铂/阿霉素联合治疗复发性卵巢癌的II期非随机研究","authors":"Ilya Pokataev, Alexey Tryakin, Alexandra Tjulandina, Mikhail Fedyanin, Sergei Tjulandin","doi":"10.1016/j.cogc.2014.06.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>This study was aimed at evaluating the efficacy and tolerability of oxaliplatin/doxorubicin combination therapy in patients with platinum-sensitive and platinum-resistant ovarian cancer.</p></div><div><h3>Materials and Methods</h3><p>Patients with recurrent ovarian cancer after 1 regimen of platinum-based chemotherapy received doxorubicin (50 mg/m<sup>2</sup> intravenously) and oxaliplatin (130 mg/m<sup>2</sup> intravenously) on day 1 every 3 weeks. The platinum-free interval was set to be < 24 months.</p></div><div><h3>Results</h3><p>A total of 33 patients were enrolled (21 platinum-resistant and 12 platinum-sensitive relapses). The response rate in platinum-resistant ovarian cancer was lower than in platinum-sensitive disease (33.4% vs. 54.5%), although the difference was not statistically significant (<em>P</em> = .59). The median progression-free survival (PFS) and overall survival in the whole cohort were 7.4 and 24.3 months, respectively. PFS in platinum-sensitive cancer was longer than in platinum-resistant cancer (10.8 vs. 6.7 months); however, this difference did not reach statistical significance (<em>P</em> = .14).</p></div><div><h3>Conclusion</h3><p>The combination of oxaliplatin/doxorubicin is an active regimen for patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 11-16"},"PeriodicalIF":0.0000,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.06.002","citationCount":"1","resultStr":"{\"title\":\"A Phase II Nonrandomized Study of Oxaliplatin/Doxorubicin Combination Therapy in the Treatment of Recurrent Ovarian Cancer\",\"authors\":\"Ilya Pokataev, Alexey Tryakin, Alexandra Tjulandina, Mikhail Fedyanin, Sergei Tjulandin\",\"doi\":\"10.1016/j.cogc.2014.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>This study was aimed at evaluating the efficacy and tolerability of oxaliplatin/doxorubicin combination therapy in patients with platinum-sensitive and platinum-resistant ovarian cancer.</p></div><div><h3>Materials and Methods</h3><p>Patients with recurrent ovarian cancer after 1 regimen of platinum-based chemotherapy received doxorubicin (50 mg/m<sup>2</sup> intravenously) and oxaliplatin (130 mg/m<sup>2</sup> intravenously) on day 1 every 3 weeks. The platinum-free interval was set to be < 24 months.</p></div><div><h3>Results</h3><p>A total of 33 patients were enrolled (21 platinum-resistant and 12 platinum-sensitive relapses). The response rate in platinum-resistant ovarian cancer was lower than in platinum-sensitive disease (33.4% vs. 54.5%), although the difference was not statistically significant (<em>P</em> = .59). The median progression-free survival (PFS) and overall survival in the whole cohort were 7.4 and 24.3 months, respectively. PFS in platinum-sensitive cancer was longer than in platinum-resistant cancer (10.8 vs. 6.7 months); however, this difference did not reach statistical significance (<em>P</em> = .14).</p></div><div><h3>Conclusion</h3><p>The combination of oxaliplatin/doxorubicin is an active regimen for patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer.</p></div>\",\"PeriodicalId\":100274,\"journal\":{\"name\":\"Clinical Ovarian and Other Gynecologic Cancer\",\"volume\":\"6 1\",\"pages\":\"Pages 11-16\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cogc.2014.06.002\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Ovarian and Other Gynecologic Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S221295531400026X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Ovarian and Other Gynecologic Cancer","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221295531400026X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Phase II Nonrandomized Study of Oxaliplatin/Doxorubicin Combination Therapy in the Treatment of Recurrent Ovarian Cancer
Introduction
This study was aimed at evaluating the efficacy and tolerability of oxaliplatin/doxorubicin combination therapy in patients with platinum-sensitive and platinum-resistant ovarian cancer.
Materials and Methods
Patients with recurrent ovarian cancer after 1 regimen of platinum-based chemotherapy received doxorubicin (50 mg/m2 intravenously) and oxaliplatin (130 mg/m2 intravenously) on day 1 every 3 weeks. The platinum-free interval was set to be < 24 months.
Results
A total of 33 patients were enrolled (21 platinum-resistant and 12 platinum-sensitive relapses). The response rate in platinum-resistant ovarian cancer was lower than in platinum-sensitive disease (33.4% vs. 54.5%), although the difference was not statistically significant (P = .59). The median progression-free survival (PFS) and overall survival in the whole cohort were 7.4 and 24.3 months, respectively. PFS in platinum-sensitive cancer was longer than in platinum-resistant cancer (10.8 vs. 6.7 months); however, this difference did not reach statistical significance (P = .14).
Conclusion
The combination of oxaliplatin/doxorubicin is an active regimen for patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
